Enantiospecific effects of chiral drugs on cytochrome P450 inhibition in vitro

References

• Agranat I, Caner H, Caldwell J. (2002). Putting chirality to work: the strategy of chiral switches. Nat Rev Drug Discovery 1:753–68
   PubMed Web of Science ®Google Scholar
• Anzenbacher P, Anzenbacherova E. (2001). Cytochromes P450 and metabolism of xenobiotics. Cell Mol Life Sci 58:737–47
   PubMed Web of Science ®Google Scholar
• Becquemont L, Mouajjah S, Escaffre O, et al. (1999). Cytochrome P-450 3A4 and 2C8 are involved in zopiclone metabolism. Drug Metab Dispos 27:1068–73
   PubMed Web of Science ®Google Scholar
• Brocks DR. (2006). Drug disposition in three dimensions: an update on stereoselectivity in pharmacokinetics. Biopharm Drug Dispos 27:387–406
   PubMed Web of Science ®Google Scholar
• Brynne N, Svanstrom C, Aberg-Wistedt A, et al. (1999). Fluoxetine inhibits the metabolism of tolterodine-pharmacokinetic implications and proposed clinical relevance. Br J Clin Pharmacol 48:553–63
   PubMed Web of Science ®Google Scholar
• Chauret N, Gauthier A, Nicoll-Griffith DA. (1998). Effect of common organic solvents on in vitro cytochrome P450-mediated metabolic activities in human liver microsomes. Drug Metab Dispos 26:1–4
   PubMed Web of Science ®Google Scholar
• Chhabra N, Aseri Ml, Padmanabhan D. (2013). A review of drug isomerism and its significance. Int J App Basic Med Res 3:16–18
   PubMedGoogle Scholar
• Copeland RA. (2000). Enzymes: a practical introduction to structure, mechanism, and data analysis. 2nd ed. New York: Wiley-VCH, Inc
   Google Scholar
• Darwish M, Bond M, Hellriegel ET, et al. (2012). Investigation of a possible interaction between quetiapine and armodafinil in patients with schizophrenia: an open-label, multiple-dose study. J Clin Pharmacokinet 52:1399–409
   PubMed Web of Science ®Google Scholar
• Darwish M, Kirby M, Robertson P, Hellriegel ET. (2008). Interaction profile of armodafinil with medications metabolized by cytochrome P450 enzymes 1A2, 3A4 and 2C19 in healthy subjects. J Clin Pharmacokinet 47:61–74
   Google Scholar
• Dilmaghanian S, Gerber JG, Filler SG, et al. (2004). Enantioselectivity of inhibition of cytochrome P450 3A4 (CYP3A4) by ketoconazole: testosterone and methadone as substrates. Chirality 16:79–85
   PubMed Web of Science ®Google Scholar
• Ekroos M, Sjorgen T. (2006). Structural basis for ligand promiscuity in cytochrome P450 3A4. Proc Natl Sci USA 103:13682–7
   PubMed Web of Science ®Google Scholar
• Franco-Salinas G, de la Rosette JJMCH, Michel MC. (2010). Pharmacokinetics and pharmacodynamics of tamsulosin in its modified-release and oral controlled absorption system formulations. Clin Pharmacokinet 49:177–88
   PubMed Web of Science ®Google Scholar
• Galetin A, Ito K, Hallifax D, Houston JB. (2005). CYP3A4 substrate selection and substitution in the prediction of potential drug-drug interactions. J Pharmacol Exp Ther 314:180–90
   PubMed Web of Science ®Google Scholar
• Greenblatt DJ, Venkatakrishnan K, Harmatz JS, et al. (2010). Sources of variability in ketoconazole inhibition of human cytochrome P450 3A in vitro. Xenobiotica 40:713–20
   PubMed Web of Science ®Google Scholar
• Greenblatt DJ, Zammit GK. (2012). Pharmacokinetic evaluation of eszopiclone: clinical and therapeutic implications. Expert Opin Drug Metab Toxicol 8:1609–18
   PubMed Web of Science ®Google Scholar
• Greenblatt DJ, Zhao Y, Venkatakrishnan K, et al. (2011). Mechanism of cytochrome P450-3A inhibition by ketoconazole. J Pharm Pharmacol 63:214–21
   PubMed Web of Science ®Google Scholar
• Grimm SW, Einolf HJ, Hall SD, et al. (2009). The conduct of in vitro studies to address time-dependent inhibition of drug-metabolizing enzymes: a perspective of the pharmaceutical research and manufacturers of America. Drug Metab Dispos 37:1355–70
   PubMed Web of Science ®Google Scholar
• Hammond KP, Nielsen C, Linnebur SA, et al. (2014). Priapism induced by boceprevir-CYP3A4 inhibition and α-adrenergic blockade: case report. Clin Infect Dis 58:e35–8
   PubMed Web of Science ®Google Scholar
• Hendrychova T, Anzenbacherova E, Hudecek J, et al. (2011). Flexibility of human cytochrome P450 enzymes: molecular dynamics and spectroscopy reveal important function-related variations. Biochim Biophys Acta 1814:58–68
   PubMed Web of Science ®Google Scholar
• Huedo-Medina TB, Kirsch I, Middlemass J, et al. (2012). Effectiveness of non-benzodiazepine hypnotics in treatment of adult insomnia: meta-analysis of data submitted to the Food and Drug Administration. BMJ 345:e8343
   PubMed Web of Science ®Google Scholar
• Ingelman-Sundberg M. (2004). Human drug metabolizing cytochrome P450 enzymes: properties and polymorphisms. Naunyn-Schmiedeberg's Arch Pharmacol 369:89–104
   Google Scholar
• Jalava KM, Olkkola KT, Neuvonen PJ. (1996). Effect of itraconazole on the pharmacokinetics and pharmacodynamics of zopiclone. Eur J Clin Pharmacol 51:331–4
   PubMed Web of Science ®Google Scholar
• Kamimura H, Oishi S, Matsushima H, et al. (1998). Identification of cytochrome P450 isozymes involved in metabolism of the a1-adrenoceptor blocker tamsulosin in human liver microsomes. Xenobiotica 28:909–22
   PubMed Web of Science ®Google Scholar
• Kim WC, Tateno A, Arakawa R, et al. (2014). In vivo activity of modafinil on dopamine transporter measured with positron emission tomography and [18F]FE-PE21. Int J Neuropsychopharmacol 17:697–703
   PubMed Web of Science ®Google Scholar
• Kingback M, Carlsson B, Ahlner J, et al. (2011). Cytochrome P450-dependent disposition of the enantiomers of citalopram and its metabolites: in vivo studies in Sprague–Dawley and dark Agouti rats. Chirality 23:172–7
   PubMed Web of Science ®Google Scholar
• Korstanje C, Krauwinkel W, van Doesum-Wolters FLC. (2011). Tamsulosin shows a higher unbound drug fraction in human prostate than in plasma: a basic for uroselectivity? Br J Clin Pharmacol 72:218–15
   PubMed Web of Science ®Google Scholar
• Lees P, Hunter RP, Reeves PT, Toutain PL. (2011). Pharmacokinetics and pharmacodynamics of stereoisomeric drugs with particular reference to bioequivalence determination. J Vet Pharmacol Therap 35:17–30
   Web of Science ®Google Scholar
• Lewis DFV. (2004). 57 varieties: the human cytochromes P450. Pharmacogenomics 5:305–18
   PubMed Web of Science ®Google Scholar
• Miller GP. (2010). Warfarin therapy: how the less interesting half just got interesting. J Thromb Haemost 8:2705–7
   PubMed Web of Science ®Google Scholar
• Nelson KL, Kamataki T, Stegeman JJ, et al. (1996). P450 superfamily: update on new sequences, gene mapping, accession numbers and nomenclature. Pharmacogenetics 6:1–42
   PubMedGoogle Scholar
• Nerurkar SG, Dighe SV, Williams RL. (1992). Bioequivalence of racemic drugs. J Clin Pharmacol 32:935–43
   PubMed Web of Science ®Google Scholar
• Noehr-Jensen L, Zwisler ST, Larsen F, et al. (2009). Escitalopram is a weak inhibitor of the CYP2D6-catalyzed O-demethylation of (+)-tramadol but does not reduce the hypoalgesic effect in experimental pain. Clin Pharmacol Ther 86:628–33
   Web of Science ®Google Scholar
• Novotna A, Krasulova K, Bartonkova I, et al. (2014b). Dual effects of ketoconazole cis-enantiomers on CYP3A4 in human hepatocytes and HepG2 cells. PLoS One 9:e111286
   PubMed Web of Science ®Google Scholar
• Novotna A, Kamenickova A, Pecova M, et al. (2014a). Profiling of enantiopure drugs towards aryl hydrocarbon (AhR), 4 glucocorticoid (GR) and pregnane X (PXR) receptors in human 5 reporter cell lines. Chem Biol Interact 208:64–76
   PubMed Web of Science ®Google Scholar
• Nunez MC, Garcia-Rubino ME, Conejo-Garcia A, et al. (2009). Homochiral drugs: a demanding tendency of the pharmaceutical industry. Curr Med Chem 16:2064–74
   PubMed Web of Science ®Google Scholar
• Pastoor D, Gobburu J. (2014). Clinical pharmacology review of escitalopram for the treatment of depression. Expert Opin Drug Metab Toxicol 10:121–8
   PubMed Web of Science ®Google Scholar
• Phillips IR, Shephard EA. (2006). Cytochrome P450 protocols. 2nd ed. Totowa: Humana Press
   Google Scholar
• Robertson P, Decory HH, Madan A, Parkinson A. (2000). In vitro inhibition and induction of human hepatic cytochrome P450 enzymes by modafinil. Drug Metab Dispos 28:664–71
   PubMed Web of Science ®Google Scholar
• Robertson P, Hellriegel ET. (2003). Clinical pharmacokinetic profile of modafinil. Clin Pharmacokinet 42:123–37
   PubMed Web of Science ®Google Scholar
• Royer-Morrot MJ, Rambourg M, Jacob I, Bauer P, Royer RJ. (1992). Determination of zopiclone in plasma using column liquid chromatography with ultraviolet detection. J Chromatogr 581:297–9
   PubMed Web of Science ®Google Scholar
• Sanchez C. (2006). The pharmacology of citalopram enantiomers: the antagonism by R-citalopram on the effects of citalopram. Basic Clin Pharmacol Toxicol 99:91–5
   PubMed Web of Science ®Google Scholar
• Schaller B. (2003). Zopiclone: some remarks on pharmacokinetics and pharmacodynamics. Swiss Med Weakly 133:100
   PubMed Web of Science ®Google Scholar
• Smith SW. (2009). Chiral toxicology: it's the same thing…only different. Toxicol Sci 110:4–30
   PubMed Web of Science ®Google Scholar
• Sun F, Sui C, Zhou Y, et al. (2013). Preparation, characterization and pharmacological evaluation of tolterodine hydrogels for the treatment of overactive bladder. Int J Pharm 454:532–8
   PubMed Web of Science ®Google Scholar
• Troost J, Tatami S, Tsuda Y, et al. (2011). Effects of strong CYP2D6 and 3A4 inhibitors, paroxetine and ketoconazole, on the pharmacokinetics and cardiovascular safety of tamsulosin. Br J Clin Pharmacol 72:247–56
   PubMed Web of Science ®Google Scholar
• Tsuchiya H, Mizogami M. (2012). The membrane interaction of drugs as one of mechanisms for their enantioselective effects. Med Hypotheses 79:65–7
   PubMed Web of Science ®Google Scholar
• Venkatakrishnan K, von Moltke LL, Greenblatt DJ. (2000). Effects of the antifungal agents on oxidative drug metabolism. Clin Pharmacokinet 38:111–18
   PubMed Web of Science ®Google Scholar
• von Moltke LL, Greenblatt DJ, Giancarlo GM, et al. (2001). Escitalopram (S-citalopram) and its metabolites in vitro: cytochromes mediating biotransformation, inhibitory effects, and comparison to R-citalopram. Drug Metab Dispos 26:1102–9
   Google Scholar
• Zanger UM, Schwab M. (2013). Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation. Pharmacol Ther 138:103–41
   PubMed Web of Science ®Google Scholar
• Zhang Z, Wong YN. (2005). Enzyme kinetics for clinically relevant CYP inhibition. Curr Drug Metab 6:241–57
   PubMed Web of Science ®Google Scholar